IKAP.F Aurinia Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
14.40 EUR
Close of Nov 13, 2026
11.56 16.40
Market cap
EUR 1.93B
P/E
7.3x
P/B
3.28x
ROE
21.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IKAP.F undervalued?

Graham number
Price14.40
Graham value13.92
Premium3.4%

IKAP.F trades 3.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aurinia Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Aurinia Pharmaceuticals Inc yet.

Aurinia Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases…

Full company profile